Ironwood Pharmaceuticals Inc (IRWD) concluded trading on Wednesday at a closing price of $1.03, with 6.7 million shares of worth about $6.9 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -74.31% during that period and on April 09, 2025 the price saw a loss of about -7.21%. Currently the company’s common shares owned by public are about 160.21M shares, out of which, 156.67M shares are available for trading.
Stock saw a price change of -28.47% in past 5 days and over the past one month there was a price change of -30.41%. Year-to-date (YTD), IRWD shares are showing a performance of -76.75% which decreased to -87.16% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.09 but also hit the highest price of $8.45 during that period. The average intraday trading volume for Ironwood Pharmaceuticals Inc shares is 3.21 million. The stock is currently trading -26.87% below its 20-day simple moving average (SMA20), while that difference is down -38.88% for SMA50 and it goes to -73.82% lower than SMA200.
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) currently have 160.21M outstanding shares and institutions hold larger chunk of about 101.75% of that.
The stock has a current market capitalization of $166.67M and its 3Y-monthly beta is at 0.47. PE ratio of stock for trailing 12 months is 95.37, while it has posted earnings per share of $0.01 in the same period. It has Quick Ratio of 4.69. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IRWD, volatility over the week remained 12.95% while standing at 9.31% over the month.
Analysts are in expectations that Ironwood Pharmaceuticals Inc (IRWD) stock would likely to be making an EPS of -0.01 in the current quarter, while forecast for next quarter EPS is 0.04 and it is 0.4 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.05 which is 0.03 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.02 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 325.00% while it is estimated to increase by 409.80% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on September 09, 2024 offering a Market perform rating for the stock and assigned a target price of $5 to it. Coverage by CapitalOne stated Ironwood Pharmaceuticals Inc (IRWD) stock as an Equal weight in their note to investors on August 08, 2024, suggesting a price target of $4 for the stock. On January 17, 2024, Craig Hallum Initiated their recommendations, while on December 14, 2023, Wells Fargo Initiated their ratings for the stock with a price target of $20. Stock get a Buy rating from Jefferies on November 09, 2023.
